Post-downstaging tumor response could expand the criteria for liver transplantation in HCC, according to positive EFS/OS results in a phase 2b/3 trial.
At the Great Debates & Updates in GI Cancer, Constantinos Sofocleous, MD, PhD, participated in a lively debate on the optimal treatment of early HCC, and spoke in favor of ablation.
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
The FDA has approved atezolizumab plus bevacizumab as a combo therapy for patients with unresectable or metastatic HCC who have not received systemic therapy.
ctDNA is a promising, emerging biomarker to monitor treatment responses and disease progression in patients with HCC.
In a phase 2 study, radioembolization yielded objective responses in patients with metastatic liver neuroendocrine neoplasms previously given peptide radionuclide therapy.
The FDA has approved nivolumab plus ipilimumab for the treatment of patients with advanced HCC previously given sorafenib.
The anti-PD-1 inhibitor camrelizumab has shown antitumor activity with manageable toxicity in pretreated patients with advanced HCC.
Though the primary end point of OS was not reached in the CheckMate 459 study, nivolumab showed clinically meaningful improvements in OS, ORR, and CR in HCC.